{"id":"umec","rwe":[{"pmid":"41753185","year":"2026","title":"Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41679900","year":"2026","title":"Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand.","finding":"","journal":"BMJ open respiratory research","studyType":"Clinical Study"},{"pmid":"41673353","year":"2026","title":"A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol.","finding":"","journal":"Pulmonary therapy","studyType":"Clinical Study"},{"pmid":"41569404","year":"2026","title":"Response to: Letter to the Editor Regarding \"Comparative Effectiveness of FF/1 UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy\".","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"},{"pmid":"41563709","year":"2026","title":"Letter to the Editor Regarding \"Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy\".","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"LOE Approaching","category":"status"},{"label":"Glaxo Grp England","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Viral upper respiratory tract infection","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Abdominal pain upper","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Toothache","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Contusion","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"1%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Atrial fibrillation","drugRate":"0.5%","severity":"serious"},{"effect":"Pneumonia","drugRate":"0.5%","severity":"serious"},{"effect":"Supraventricular tachycardia","drugRate":"0.5%","severity":"serious"},{"effect":"Supraventricular extrasystoles","drugRate":"0.5%","severity":"serious"},{"effect":"Sinus tachycardia","drugRate":"0.5%","severity":"serious"},{"effect":"Idioventricular rhythm","drugRate":"0.5%","severity":"serious"},{"effect":"Depression","drugRate":"0.5%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Glaxo Grp England","patents":[{"applNo":"N205382","source":"FDA Orange Book","status":"Active","expires":"Dec 18, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7488827","drugSubstance":true}],"pricing":[],"allNames":["umec"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2027-12-18","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7488827 expires"}],"approvals":[],"ecosystem":[],"mechanism":{"target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","modality":"Small Molecule","explanation":"Imagine UmeC as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that can help to treat a particular condition. However, without more information, it's difficult to say exactly how UmeC works or what condition it's intended to treat.","oneSentence":"UmeC is a small molecule drug that works by interacting with a specific target in the body.","technicalDetail":"UmeC's mechanism of action is not well understood, but it is believed to involve the inhibition of a specific enzyme or receptor, leading to a cascade of downstream effects that may contribute to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=umec","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=umec","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:26:05.296968","biosimilars":[],"competitors":[],"genericName":"umec","indications":{"approved":[{"name":"Asthma","diseaseId":"asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic bronchitis","diseaseId":"chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic obstructive lung disease","diseaseId":"chronic-obstructive-lung-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary emphysema","diseaseId":"pulmonary-emphysema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Glaxo Grp England","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06372496","phase":"PHASE4","title":"Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-04-16","conditions":["Asthma"],"enrollment":1366,"completionDate":"2027-03-31"},{"nctId":"NCT06428461","phase":"NA","title":"Evaluation of Supraclavicular Brachial Plexus Blocks at Various Volumes: Impact on Optic Nerve Sheath Diameter","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2024-05-20","conditions":["Upper Limb Injury","Intracranial Pressure Increase"],"enrollment":64,"completionDate":"2025-04-10"},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":["Asthma"],"enrollment":20,"completionDate":"2030-12-31"},{"nctId":"NCT05535972","phase":"PHASE4","title":"To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":463,"completionDate":"2023-09-25"},{"nctId":"NCT05757102","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-04-25","conditions":["Asthma"],"enrollment":292,"completionDate":"2027-01-15"},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":60,"completionDate":"2027-10"},{"nctId":"NCT04651777","phase":"PHASE3","title":"Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Grace Parraga","startDate":"2022-08-08","conditions":["Asthma"],"enrollment":31,"completionDate":"2025-12"},{"nctId":"NCT04937387","phase":"PHASE3","title":"Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-07-29","conditions":["Asthma"],"enrollment":359,"completionDate":"2024-08-05"},{"nctId":"NCT04923347","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-06-06","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":229,"completionDate":"2024-03-14"},{"nctId":"NCT05127304","phase":"","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-26","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":11316,"completionDate":"2022-02-03"},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":800,"completionDate":"2019-07-17"},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":["Asthma"],"enrollment":2436,"completionDate":"2019-02-22"},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":732,"completionDate":"2019-03-18"},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":["Asthma"],"enrollment":425,"completionDate":"2018-05-30"},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":729,"completionDate":"2019-03-14"},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":3109,"completionDate":"2019-10-10"},{"nctId":"NCT03543176","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-05-31","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":789,"completionDate":"2019-08-21"},{"nctId":"NCT02184611","phase":"PHASE3","title":"A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-09","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":308,"completionDate":"2017-11-08"},{"nctId":"NCT03184987","phase":"PHASE3","title":"A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-22","conditions":["Asthma"],"enrollment":111,"completionDate":"2019-06-25"},{"nctId":"NCT03949842","phase":"PHASE4","title":"Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-06-27","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":0,"completionDate":"2022-11-30"},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":2696,"completionDate":"2018-06-18"},{"nctId":"NCT03046069","phase":"","title":"FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-20","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":634,"completionDate":"2018-02-23"},{"nctId":"NCT02570165","phase":"PHASE2","title":"Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-06","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":325,"completionDate":"2016-07-06"},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1055,"completionDate":"2017-05-23"},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":["Asthma"],"enrollment":0,"completionDate":"2021-02-03"},{"nctId":"NCT02164513","phase":"PHASE3","title":"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-30","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":10355,"completionDate":"2017-07-17"},{"nctId":"NCT02275052","phase":"PHASE4","title":"A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":198,"completionDate":"2016-06-02"},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1811,"completionDate":"2016-04-07"},{"nctId":"NCT02799784","phase":"PHASE4","title":"An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-14","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":236,"completionDate":"2017-04-27"},{"nctId":"NCT02236611","phase":"PHASE4","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-26","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1036,"completionDate":"2015-06-02"},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":967,"completionDate":"2015-05-04"},{"nctId":"NCT02014480","phase":"PHASE3","title":"A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":207,"completionDate":"2013-06-11"},{"nctId":"NCT02673619","phase":"PHASE2","title":"A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2016-03-07","conditions":["Hyperhidrosis"],"enrollment":58,"completionDate":"2016-12-08"},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":1017,"completionDate":"2015-06-15"},{"nctId":"NCT01899742","phase":"PHASE3","title":"The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-15","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":497,"completionDate":"2015-07-22"},{"nctId":"NCT02152605","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":498,"completionDate":"2015-03-05"},{"nctId":"NCT01957163","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":619,"completionDate":"2014-04-01"},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":707,"completionDate":"2013-10-25"},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":700,"completionDate":"2014-01-09"},{"nctId":"NCT02164539","phase":"PHASE2","title":"Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-01","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":338,"completionDate":"2015-07-18"},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":717,"completionDate":"2013-10-07"},{"nctId":"NCT00515502","phase":"PHASE2","title":"Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-21","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":24,"completionDate":"2007-11-06"},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":236,"completionDate":"2015-03-24"},{"nctId":"NCT01691547","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-17","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":44,"completionDate":"2013-03-08"},{"nctId":"NCT01725685","phase":"PHASE1","title":"To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-08","conditions":["Asthma"],"enrollment":18,"completionDate":"2013-01-02"},{"nctId":"NCT01899638","phase":"PHASE1","title":"Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-20","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":20,"completionDate":"2013-07-25"},{"nctId":"NCT01894386","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-15","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":48,"completionDate":"2013-09-26"},{"nctId":"NCT02119286","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":620,"completionDate":"2014-04"},{"nctId":"NCT02837380","phase":"PHASE1","title":"A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":16,"completionDate":"2016-11"},{"nctId":"NCT02731846","phase":"PHASE3","title":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-06","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":0,"completionDate":"2016-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Glaxo Grp England","relationship":"Original Developer"}],"publicationCount":261,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"originalDeveloper":"Glaxo Grp England","recentPublications":[{"date":"2026 Feb 14","pmid":"41753185","title":"Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?","journal":"Journal of clinical medicine"},{"date":"2026 Feb 12","pmid":"41679900","title":"Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand.","journal":"BMJ open respiratory research"},{"date":"2026 Mar","pmid":"41673353","title":"A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol.","journal":"Pulmonary therapy"},{"date":"2026 Mar","pmid":"41569404","title":"Response to: Letter to the Editor Regarding \"Comparative Effectiveness of FF/1 UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy\".","journal":"Advances in therapy"},{"date":"2026 Mar","pmid":"41563709","title":"Letter to the Editor Regarding \"Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy\".","journal":"Advances in therapy"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","brandName":"UMEC","companyName":"Glaxo Grp England","companyId":"glaxo-grp-england","modality":"Small molecule","firstApprovalDate":"","aiSummary":"UmeC is a small molecule drug developed by Glaxo Group in England, currently owned by the same company. Unfortunately, there is limited information available on its target, drug class, or approved indications. As a result, its mechanism of action, safety considerations, and commercial status are unknown. Further research is needed to understand the potential benefits and risks of UmeC. Its status as a patented or generic medication also remains unclear.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}